CONMED (CNMD) Peer Comparison

$49.32

$-0.10 (-0.20%)

As on 04-Sep-2026 16:00EDT

Market cap

$1,477 Mln

Revenue (TTM)

$1,373 Mln

P/E Ratio

26.7

P/B Ratio

1.4

Div. Yield

0.4 %

Edit

	CONMED (CNMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	1,477	12,650	10,638	9,762	9,459
Revenue ($ Mln)	1,373	1,505	613	2,589	785
Net Profit ($ Mln)	56.50	160.59	-188.05	222.40	41.54
Net Margin (%)	4.12	10.67	-30.68	8.59	5.29
RoE (%)	5.45	10.86	-28.10	3.04	1.97
Price to Earnings	26.66	79.29	--	44.47	232.78
Price-To-Book	1.42	8.31	15.27	1.36	4.62

Income Statement ($ Mln)

	CONMED (CNMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	1,372.59	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	620.40	483.98	127.96	1,245.50	384.30
Gross Profit	725.38	942.44	393.22	1,343.60	347.62
Operating Expenses	604.10	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	148.09	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	83.23	203.83	-192.83	350.40	52.15
Provision for Tax	26.73	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	56.50	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

	CONMED (CNMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	1,041.39	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	803.52	210.18	135.71	2,116.80	705.49
Current Liabilities	455.40	233.78	102.33	961.30	132.66
Total Liabilities	2,325.75	1,826.52	893.49	10,576.50	2,949.70

	CONMED (CNMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	1,624.64	630.60	404.74	7,231.50	1,749.63
Current Assets	675.67	1,344.12	515.78	3,020.50	1,200.55
Total Assets	2,325.75	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	834.25	212.71	102.84	1,203.70	690.94
Net Current Assets	220.27	1,110.35	413.45	2,059.20	1,067.90

	CONMED (CNMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	170.69	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-20.96	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	-135.82	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

	CONMED (CNMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	2.52	11.76	-22.53	8.98	1.79
ROE (%)	5.45	10.86	-28.10	3.04	1.97
ROA (%)	2.10	7.95	-18.00	2.02	1.36
EBIT Margin (%)	8.24	13.63	-30.58	-5.99	9.87
Net Margin (%)	4.12	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	CONMED (CNMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	3.58	17.55	41.55	1.37	16.49
EBIT Growth (%)	-34.18	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	-48.73	8.72	-102.66	-30.32	400.42
EPS Growth (%)	-47.81	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	7.07	17.33	-12.65	2.19	2.16

	CONMED (CNMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	26.77	68.93	-34.59	--	189.42
Price / Book Value	1.42	8.31	15.27	--	4.62
Dividend Yield (%)	0.40	0.00	0.00	--	0.00
EV/EBITDA	12.62	55.45	-73.80	--	77.00
Market Cap ($ Cr)	--	--	--	--	--

	CONMED (CNMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.63	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.17	0.01	0.00	0.06	0.01
Current Ratio	1.48	5.75	5.04	3.14	9.05
Quick Ratio	0.69	3.86	4.46	2.33	7.64
Interest Coverage	3.78	157.91	-38.31	8.18	1.92

	CONMED (CNMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	17.47	12.65	22.67	17.06	20.09
Asset Turnover	0.51	0.74	0.59	0.24	0.26
Receivable days	64.52	46.54	60.95	65.39	72.41
Inventory Days	197.58	331.92	193.84	221.09	146.53
Payable days	55.11	26.16	60.19	37.02	29.05
Cash Conversion Cycle	206.98	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.